KALV - CIK 0001348911
The table below shows KalVista Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $229.34M | $31.79M | $56.24M | $30.73M | $50.59M | $15.79M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | $3.43M | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $320.15M |
| $225.69M |
| $172.33M |
| $193.65M |
| $264.26M |
| $88.70M |
| Property, plant & equipment | $3.03M | $2.23M | $2.95M | $2.18M | $1.79M | $2.04M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $335.38M | $235.40M | $183.20M | $203.88M | $272.01M | $92.53M |
| Accounts payable | $8.27M | $9.11M | $4.82M | $3.64M | $1.98M | $1.68M |
| Total current liabilities | $57.35M | $22.81M | $15.03M | $11.58M | $9.77M | $7.72M |
| Long-term debt | $172.21M | - | - | - | - | - |
| Total liabilities | $338.09M | - | - | - | - | - |
| Retained earnings | -$762.69M | -$469.73M | -$343.08M | -$250.18M | -$167.84M | -$121.59M |
| Total equity | -$2.71M | $206.58M | $161.03M | $185.09M | $257.19M | $83.75M |